Filtered By:
Source: Clinical Cancer Research
Drug: Taxotere
This page shows you your search results in order of date.
Order by Relevance | Date
Total 43 results found since Jan 2013.
Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)
CONCLUSIONS: High immune features predict docetaxel response, and high DDR signature scores predict carboplatin response in treatment-naïve mTNBC. Integrating multimodal DDR and immune-related markers identifies subgroups with differential treatment sensitivity. Treatment options for patients with immune-low and DDR-proficient tumors remains an outstanding need. Caution is needed using PT-derived transcriptional signatures to direct treatment in mTNBC, particularly DDR-related markers following prior chemotherapy.PMID:37574209 | DOI:10.1158/1078-0432.CCR-23-0370
Source: Clinical Cancer Research - August 13, 2023 Category: Cancer & Oncology Authors: Holly Tovey Orsolya Sipos Joel S Parker Katherine A Hoadley Jelmar Quist Sarah Kernaghan Lucy Kilburn Roberto Salgado Sherene Loi Richard D Kennedy Ioannis Roxanis Patrycja Gazinska Sarah E Pinder Judith Bliss Charles M Perou Syed Haider Anita Grigoriadis Source Type: research
Phase II study of docetaxel and trametinib in patients with KRAS mutation positive recurrent non-small cell lung cancer (NSCLC) (SWOG S1507, NCT-02642042)
CONCLUSIONS: RRs were significantly improved in the overall population. Contrary to pre-clinical studies, the combination showed no improvement in efficacy in G12C patients. Co-mutations may influence therapeutic efficacy of KRAS directed therapies and are worthy of further evaluation.PMID:37233987 | DOI:10.1158/1078-0432.CCR-22-3947
Source: Clinical Cancer Research - May 26, 2023 Category: Cancer & Oncology Authors: Shirish M Gadgeel Jieling Miao Jonathan W Riess James Moon Philip C Mack Gregory J Gerstner Timothy F Burns Asma Taj Wallace L Akerley Konstantin H Dragnev Noel Laudi Mary W Redman Jhanelle E Gray David R Gandara Karen Kelly Source Type: research
The GENIE BPC NSCLC cohort: a real-world repository integrating standardized clinical and genomic data for 1,846 patients with non-small cell lung cancer
CONCLUSIONS: The GENIE BPC cohort provides comprehensive clinico-genomic data for patients with NSCLC, which can improve understanding of real-world patient outcomes.PMID:37223888 | DOI:10.1158/1078-0432.CCR-23-0580
Source: Clinical Cancer Research - May 24, 2023 Category: Cancer & Oncology Authors: Noura J Choudhury Jessica A Lavery Samantha Brown Ino de Bruijn Justin Jee Thinh Ngoc Tran Hira Rizvi Kathryn C Arbour Karissa Whiting Ronglai Shen Matthew Hellmann Philippe L Bedard Celeste Yu Natasha Leighl Michele LeNoue-Newton Christine Micheel Jeremy Source Type: research
Survival outcomes, digital TILs and on-treatment PET/CT during neoadjuvant therapy for HER2-positive breast cancer: results from the randomized PREDIX HER2 trial
CONCLUSIONS: Long-term outcomes following neoadjuvant T-DM1 were similar to neoadjuvant THP. SUVmax after two cycles of neoadjuvant therapy for HER2-positive breast cancer may be an independent predictor of both short- and long-term outcomes. Combined assessment with TILs may facilitate early selection of poor responders for alternative treatment strategies.PMID:36449695 | DOI:10.1158/1078-0432.CCR-22-2829
Source: Clinical Cancer Research - November 30, 2022 Category: Cancer & Oncology Authors: Alexios Matikas Hemming Johansson Per Gryb äck Judith Bj öhle Balazs Acs Ceren Boyaci Tobias Lekberg Hanna Fredholm Ellinor Elinder Sara Margolin Erika Isaksson-Friman Ana Bosch Henrik Lindman Jamila Arda Anne Andersson Susanne Agartz Mats Hellstr öm I Source Type: research
Phase II trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody Armed Activated T Cells in Metastatic Castrate Resistant Prostate Cancer
CONCLUSIONS: The safety and promising efficacy makes this combination worthy of future investigation in mCRPC.PMID:36255393 | DOI:10.1158/1078-0432.CCR-22-1601
Source: Clinical Cancer Research - October 18, 2022 Category: Cancer & Oncology Authors: Ulka N Vaishampayan Archana Thakur Wei Chen Abhinav Deol Meera Patel Kimberlee Dobson Brenda Dickow Dana Schalk Amy Schienschang Sarah Whitaker Amanda Polend Joseph A Fontana Elisabeth I Heath Lawrence G Lum Source Type: research
SPOP mutations as a Predictive Biomarker for Androgen Receptor-Axis-Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer
CONCLUSIONS: In real-world settings, SPOP mutations were associated with improved outcomes to ADT plus ARAT (but not ADT plus docetaxel) in dn-mCSPC patients. This may serve as a predictive biomarker to guide treatment selection for mCSPC patients.PMID:36088616 | DOI:10.1158/1078-0432.CCR-22-2228
Source: Clinical Cancer Research - September 11, 2022 Category: Cancer & Oncology Authors: Umang Swami Ryon P Graf Roberto H Nussenzveig Virginia Fisher Hanna Tukachinsky Alexa B Schrock Gerald Li Jeffrey S Ross Nicolas Sayegh Nishita Tripathi Vinay Mathew Thomas Geoffrey R Oxnard Emmanuel S Antonarakis Neeraj Agarwal Source Type: research
A randomized comparison of nivolumab versus nivolumab + docetaxel for previously treated advanced or recurrent ICI-na ïve non-small-cell lung cancer: TORG1630
CONCLUSIONS: Despite the slightly elevated toxicity, the addition of docetaxel to nivolumab has significantly prolonged the OS and PFS of patients with previously treated ICI-naïve NSCLC.PMID:35980349 | DOI:10.1158/1078-0432.CCR-22-1687
Source: Clinical Cancer Research - August 18, 2022 Category: Cancer & Oncology Authors: Yuri Taniguchi Tsuneo Shimokawa Yuichi Takiguchi Toshihiro Misumi Yukiko Nakamura Yosuke Kawashima Naoki Furuya Yoshimasa Shiraishi Toshiyuki Harada Hisashi Tanaka Satoru Miura Ayumi Uchiyama Yoshiro Nakahara Takaaki Tokito Katsuhiko Naoki Akihiro Bessho Source Type: research
Neoadjuvant Chemoimmunotherapy for the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: A Single-Arm Phase 2 Clinical Trial
CONCLUSIONS: Neoadjuvant chemotherapy plus camrelizumab for locally advanced HNSCC showed high ORR, pCR, and MPR rates, with an acceptable safety profile. These data support further evaluation of neoadjuvant chemoimmunotherapy for the treatment of locally advanced HNSCC.PMID:35766967 | DOI:10.1158/1078-0432.CCR-22-0666
Source: Clinical Cancer Research - June 29, 2022 Category: Cancer & Oncology Authors: Zhanjie Zhang Bian Wu Gang Peng Guixiang Xiao Jing Huang Qian Ding Chengzhang Yang Xingao Xiong Hui Ma Liangliang Shi Jinsong Yang Xiaohua Hong Jielin Wei You Qin Chao Wan Yi Zhong Yan Zhou Xueyan Zhao Yangming Leng Tao Zhang Gang Wu Min Yao Xiaomeng Zhan Source Type: research
